IL222885B - cgrp antibodies - Google Patents

cgrp antibodies

Info

Publication number
IL222885B
IL222885B IL222885A IL22288512A IL222885B IL 222885 B IL222885 B IL 222885B IL 222885 A IL222885 A IL 222885A IL 22288512 A IL22288512 A IL 22288512A IL 222885 B IL222885 B IL 222885B
Authority
IL
Israel
Prior art keywords
cgrp antibodies
cgrp
antibodies
Prior art date
Application number
IL222885A
Other languages
English (en)
Hebrew (he)
Other versions
IL222885A0 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL222885A0 publication Critical patent/IL222885A0/en
Publication of IL222885B publication Critical patent/IL222885B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57527—Calcitonin gene related peptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL222885A 2010-06-10 2012-11-05 cgrp antibodies IL222885B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35332310P 2010-06-10 2010-06-10
PCT/US2011/039381 WO2011156324A1 (en) 2010-06-10 2011-06-07 Cgrp antibodies

Publications (2)

Publication Number Publication Date
IL222885A0 IL222885A0 (en) 2012-12-31
IL222885B true IL222885B (en) 2019-09-26

Family

ID=45096388

Family Applications (2)

Application Number Title Priority Date Filing Date
IL222885A IL222885B (en) 2010-06-10 2012-11-05 cgrp antibodies
IL242409A IL242409B (en) 2010-06-10 2015-11-02 cgrp antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL242409A IL242409B (en) 2010-06-10 2015-11-02 cgrp antibodies

Country Status (34)

Country Link
US (3) US9073991B2 (sl)
EP (2) EP3318272B1 (sl)
JP (2) JP6021806B2 (sl)
KR (1) KR101489566B1 (sl)
CN (2) CN102946905B (sl)
AR (1) AR081434A1 (sl)
AU (1) AU2011265050B2 (sl)
BR (1) BR112012031501B1 (sl)
CA (1) CA2802102C (sl)
CY (2) CY1119789T1 (sl)
DK (1) DK2579894T3 (sl)
EA (1) EA022931B1 (sl)
ES (2) ES2656000T3 (sl)
HK (1) HK1203211A1 (sl)
HR (1) HRP20171992T1 (sl)
HU (2) HUE038135T2 (sl)
IL (2) IL222885B (sl)
JO (1) JO3330B1 (sl)
LT (2) LT2579894T (sl)
LU (1) LUC00112I2 (sl)
ME (1) ME02862B (sl)
MX (2) MX340999B (sl)
NL (1) NL300979I2 (sl)
NO (2) NO2579894T3 (sl)
NZ (1) NZ603607A (sl)
PL (1) PL2579894T3 (sl)
PT (1) PT2579894T (sl)
RS (1) RS56638B1 (sl)
SG (1) SG185648A1 (sl)
SI (1) SI2579894T1 (sl)
TW (1) TWI423818B (sl)
UA (1) UA109658C2 (sl)
WO (1) WO2011156324A1 (sl)
ZA (1) ZA201208996B (sl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2433251T5 (es) 2005-11-14 2020-03-13 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina y procedimientos que utilizan los mismos
RU2522493C2 (ru) 2008-03-04 2014-07-20 Пфайзер Лимитед Способы лечения хронической боли
KR101519192B1 (ko) 2009-08-28 2015-05-11 리나트 뉴로사이언스 코프. 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법
AR081434A1 (es) * 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
US9855332B2 (en) 2011-05-20 2018-01-02 Alderbio Holdings Llc Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels
AU2012258980B8 (en) 2011-05-20 2017-06-15 H. Lundbeck A/S Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
TWI646111B (zh) * 2011-05-20 2019-01-01 艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ－ｃｇｒｐ）組成物及其用途
CN104662044B (zh) 2012-08-24 2018-10-30 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
US10556945B2 (en) * 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX2016012188A (es) 2014-03-21 2017-04-27 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
AU2015335828B2 (en) 2014-10-24 2018-08-23 Merck Sharp & Dohme Llc Co-agonists of the glucagon and GLP-1 receptors
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
KR20180054851A (ko) * 2015-10-30 2018-05-24 일라이 릴리 앤드 캄파니 항-cgrp/항-il-23 이중특이적 항체 및 그의 용도
CN105483091A (zh) * 2015-12-29 2016-04-13 天津三箭生物技术股份有限公司 小鼠抗人Calcitonin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株
BR112018010596A2 (pt) * 2016-01-28 2018-11-13 Lilly Co Eli anticorpos para cgrp e usos dos mesmos
JP6815407B2 (ja) 2016-02-01 2021-01-20 イーライ リリー アンド カンパニー 副甲状腺ホルモン−抗ｒａｎｋｌ抗体融合化合物
IL299099A (en) 2016-06-27 2023-02-01 Univ California Combinations of cancer treatments
KR20190066607A (ko) * 2016-09-23 2019-06-13 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
WO2018055573A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating cluster headache
WO2018160897A1 (en) 2017-03-02 2018-09-07 Beth Israel Deaconess Medical Center, Inc. Preventing post-ictal headaches
TW201902926A (zh) 2017-05-03 2019-01-16 美商美國禮來大藥廠 抗cgrp／抗il-23雙特異性抗體及其用途
JP2020525445A (ja) 2017-06-21 2020-08-27 セファロン・インコーポレイテッドＣｅｐｈａｌｏｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ カチオン交換クロマトグラフィーの洗浄緩衝液
TWI754772B (zh) 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
JP7339262B2 (ja) 2018-01-12 2023-09-05 アムジェン インコーポレイテッド Ｐａｃ１抗体及びその使用
WO2019231800A1 (en) 2018-05-31 2019-12-05 Eli Lilly And Company Anti-cgrp antibodies for treating menstrual-related migraines
EP3840836A1 (en) 2018-08-22 2021-06-30 Eli Lilly and Company Anti-cgrp antibodies for treatment-resistant patients
JP2022516956A (ja) 2019-01-08 2022-03-03 ハー・ルンドベック・アクチエゼルスカベット 抗ｃｇｒｐ抗体を用いた頭痛の急性治療及び迅速治療
EP3744400A1 (en) * 2019-05-28 2020-12-02 Etablissement Français du Sang Car-t cells targeting il-1rap and their use in acute myeloid leukemia (aml)
WO2020239014A1 (zh) * 2019-05-30 2020-12-03 山东博安生物技术有限公司 抗cgrp抗体及其应用
JP7551744B2 (ja) 2019-10-15 2024-09-17 イーライ リリー アンド カンパニー 組換え操作された、リパーゼ／エステラーゼ欠損哺乳動物細胞株
WO2022185224A1 (en) 2021-03-02 2022-09-09 Mark Hasleton Treatment and/or reduction of occurrence of migraine
WO2023161526A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
WO2024032750A1 (zh) * 2022-08-11 2024-02-15 上海君实生物医药科技股份有限公司 抗cgrp抗体及用途
CN118271438B (zh) * 2024-05-27 2024-08-30 上海宏成药业有限公司 抗cgrp抗体或其抗原结合片段及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5795965A (en) * 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
WO1992022653A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
AU2006234847A1 (en) * 2005-04-08 2006-10-19 Medimmune, Llc Antibodies against mammalian metapneumovirus
ES2433251T5 (es) * 2005-11-14 2020-03-13 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina y procedimientos que utilizan los mismos
WO2007076336A1 (en) * 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
BRPI0908276B8 (pt) * 2008-03-04 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite
RU2522493C2 (ru) * 2008-03-04 2014-07-20 Пфайзер Лимитед Способы лечения хронической боли
AR081434A1 (es) * 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo

Also Published As

Publication number Publication date
TWI423818B (zh) 2014-01-21
US20110305711A1 (en) 2011-12-15
PL2579894T3 (pl) 2018-04-30
IL242409B (en) 2020-07-30
US9073991B2 (en) 2015-07-07
CN104292332A (zh) 2015-01-21
DK2579894T3 (en) 2018-01-15
KR101489566B1 (ko) 2015-02-03
TW201210618A (en) 2012-03-16
CY2019017I2 (el) 2020-05-29
CN104292332B (zh) 2019-11-01
HK1203211A1 (en) 2015-10-23
CY2019017I1 (el) 2020-05-29
LTPA2019011I1 (lt) 2019-05-10
PT2579894T (pt) 2018-02-06
LT2579894T (lt) 2018-02-26
ME02862B (me) 2018-04-20
NZ603607A (en) 2014-09-26
SG185648A1 (en) 2012-12-28
JO3330B1 (ar) 2019-03-13
LUC00112I2 (sl) 2019-12-27
SI2579894T1 (sl) 2018-01-31
US20170073403A1 (en) 2017-03-16
EP3318272A1 (en) 2018-05-09
HRP20171992T1 (hr) 2018-02-09
JP6466883B2 (ja) 2019-02-06
HUS1900020I1 (hu) 2019-05-28
US20150259415A1 (en) 2015-09-17
ZA201208996B (en) 2014-05-28
LTC2579894I2 (lt) 2020-03-25
ES2930321T3 (es) 2022-12-09
EA201270769A1 (ru) 2013-04-30
EP2579894A4 (en) 2013-12-04
JP6021806B2 (ja) 2016-11-09
CA2802102C (en) 2016-07-26
BR112012031501A2 (pt) 2016-10-25
RS56638B1 (sr) 2018-03-30
NO2019017I1 (no) 2019-04-05
EA022931B1 (ru) 2016-03-31
NO2579894T3 (sl) 2018-04-21
EP3318272B1 (en) 2022-08-10
KR20130034024A (ko) 2013-04-04
AR081434A1 (es) 2012-08-29
AU2011265050A1 (en) 2012-11-08
MX340999B (es) 2016-08-03
NL300979I1 (nl) 2019-04-17
EP2579894A1 (en) 2013-04-17
AU2011265050B2 (en) 2013-06-27
ES2656000T3 (es) 2018-02-22
CN102946905A (zh) 2013-02-27
IL222885A0 (en) 2012-12-31
JP2017014203A (ja) 2017-01-19
MX2012014480A (es) 2013-02-07
HUE038135T2 (hu) 2018-09-28
US9505838B2 (en) 2016-11-29
UA109658C2 (xx) 2015-09-25
CY1119789T1 (el) 2018-06-27
CN102946905B (zh) 2014-10-15
NL300979I2 (nl) 2019-07-11
WO2011156324A1 (en) 2011-12-15
LUC00112I1 (sl) 2019-04-10
MX363209B (es) 2019-03-14
CA2802102A1 (en) 2011-12-15
JP2013532143A (ja) 2013-08-15
EP2579894B1 (en) 2017-11-22
BR112012031501B1 (pt) 2020-02-11

Similar Documents

Publication Publication Date Title
HUS1900020I1 (hu) CGRP ellenanyagok
HRP20180952T1 (hr) Anti-dll3 antitijelo
ZA201209004B (en) Anti-fgfr2 antibodies
HUE040213T2 (hu) Anti-TIM antitest
GB201000467D0 (en) Antibodies
IL221371A0 (en) Anti-lrp6 antibodies
DK3904391T3 (en) Monoclonal antibodies against c-met
PL2616489T3 (pl) Przeciwciało anty-huTNFR1
EP2543730A4 (en) VARIANT OF A CONSTANT ANTIBODY REGION
HK1194388A1 (zh) 抗缺刻蛋白 抗體
PL2603528T3 (pl) Przeciwciała Fab-glikozylowane
GB201020738D0 (en) Antibodies
GB201002238D0 (en) Antibodies
ZA201302459B (en) Antibodies
GB201007957D0 (en) Antibody
GB201017780D0 (en) Antibody
GB201020751D0 (en) Antibodies
GB201005062D0 (en) Antibodies

Legal Events

Date Code Title Description
FF Patent granted
EXTF Application for patent extension filed

Filing date: 20200204

KB Patent renewed
KB Patent renewed